 Overview Annual Report and Accounts 2009
www.omegadiagnostics.com
10
Chairman’s Statement
Dear Shareholder
I am pleased to report that the Group has  
made sustained progress in the year with  
growth in turnover and profitability across  
the Group.
David Evans 
Non-executive Chairman 
6 July 2009
Strategy
The acquisition of Genesis Diagnostics (‘Genesis’) and Cambridge 
Nu t r it i ona l 	 S cie nc e s 	 ( ‘ CNS ’ ) 	 ha s 	 suc c e s sf u ll y 	 f u lf ille d 	 one 	 o f 	 o ur	
strategic aims of acquiring profitable companies with complementary 
products	 that	 drive	 grow th.	 T urnover	 has	 increased	 across	 all	 group	
div isions 	 a nd 	 in 	 most 	 o f 	 t he 	 r e gions 	 we 	 se ll 	 t o 	 a r ound 	 t he 	 wor ld . 	 T he	
Group has been able to make good use of its expanded distribution 
net w or k 	 in 	 achie v ing 	 t he 	 r oll-ou t 	 o f 	 t he 	 G e na r ra y t
™
 food intolerance 
assay	 where	 systems	 have	 been	 placed	 in	 a	 number	 of	 countries	 for	
evaluation	 purposes	 and	 there	 has	 also	 been	 some	 cross-selling	 of	
t he 	 e sta blis he d 	 G e ne sis 	 au t oimm une 	 a nd 	 O m e g a 	 D iagnost i c s 	 L im it e d	
( ‘ O D L ’ ) 	 i n f e c t i o u s 	 d is e a s e 	 t e s t s 	 i n t o 	 t h e 	 e x p a n d e d 	 n e t w o r k . 	 T h r o u g h	 
its	 increased	 sales	 and	 marketing	 resource,	 new	 distributors	 have	 
a lso 	 b e e n 	 a p p oin t e d 	 in 	 m u lt iple 	 t e r r it or ie s 	 f or 	 t he 	 F o o d 	 D e t e ct i v e
™
 
consumer	 test.	 Key	 to	 continued	 organic	 grow th	 will	 be	 the	 deliver y	 
of new products utilising the microarray and macroarray platforms  
and	 development	 activity	 continues	 with	 this	 aim	 in	 mind.
A planned acquisition last year had to be aborted as it was not 
possible to raise sufficient funds in deteriorating financial markets 
t o	 m e e t	 t h e	 v e n d o r s ’	 p r i c e	 e x p e c t a t i o n s.	 T h e	 G r o u p	 h a s	 i n c u r r e d	
a n	 e x c e p t i o n a l	 c o s t	 o f	 £ 8 0 k	 i n	 r e l a t i o n	 t o	 t h i s	 a b o r t e d	 t r a n s a c t i o n .	
W h i l s t	 t h i s	 m a y	 b e	 s e e n	 a s	 d i s a p p o i n t i n g ,	 t h e	 G r o u p	 s t i l l	 b e l i e v e s	 
that acquisition opportunities exist which are capable of being 
funded and the Board continues to pursue this aspect of its strategy 
a s	 a	 v i a b l e	 wa y	 o f	 a c h i e v i n g	 g r o w t h	 f o r	 t h e	 G r o u p	 a n d	 i n c r e a s i n g	
s h a re h o l d e r	 val ue.
Financial
T h e	 r e s u l t s	 f o r	 t h e	 y e a r	 i n c l u d e	 a	 f u l l	 t we l v e	 m o n t h s	 f o r	 G e n e s i s	
a n d	 C N S,	 a l b e i t ,	 t h e	 c o m p a r a t i v e s	 o n l y	 i n c l u d e	 s e v e n	 m o n t h s	 i n	
t h e	 p r i o r	 y e a r	 t o	 3 1	 M a r c h	 2 0 0 8.
T u r n o v e r	 f o r	 t h e	 G r o u p	 i n c r e a s e d	 t o	 £5 . 4	 m i l l i o n	 ( 2 0 0 8 :	 £ 3 . 5	 m i l l i o n )	
a n	 i n c r e a s e	 o f	 5 6 %	 r e f l e c t i n g	 t h e	 t we l v e	 m o n t h	 c o n t r i b u t i o n	 f r o m	
G e n e s i s	 a n d	 C N S .	 H o we v e r ,	 i t	 i s	 p a r t i c u l a r l y	 p l e a s i n g	 t o	 r e p o r t	
u n d e r l y i n g	 l i k e - f o r - l i k e	 g r o w t h	 i n	 t u r n o v e r	 o f	 2 0 %	 d e s p i t e	 d i f f i c u l t	
economic conditions.
T h e	 G r o u p	 a c h i e v e d	 a n	 E B I T D A	 b e f o r e	 e x c e p t i o n a l	 i t e m s	 o f	
£ 9 1 5 k	 ( 2 0 0 8 :	 £ 4 1 7 k )	 a n d	 o p e r a t i n g	 p r o f i t	 b e f o r e	 e x c e p t i o n a l	
i t e m s	 i n c r e a s e d	 t o	 £ 6 5 3 k	 ( 2 0 0 8 :	 £ 29 8 k ) ,	 a g a i n	 w i t h	 t h e	 b e n e f i t	
o f	 a	 f u l l	 y e a r	 f r o m	 G e n e s i s	 a n d	 C N S .
In terms of our results as compared to the external market forecast,  
t he 	 Gr oup 	 a chie v ed 	 an 	 a dj us t ed 	 pr o fit 	 be f or e 	 t a x 	 o f 	 £5 3 1 k 	 ( 2 008 : 	 £ 82 k ) .	
This	 figure	 is	 arrived	 at	 by	 taking	 headline	 profit	 before	 tax	 of	 £26 7k	 and	
then adding back analyst-adjusted items including IFRS-related net 
discount	 charges	 of	 £ 7k,	 exceptional	 costs	 of	 £80k,	 amortisation	 of	
intangible	 assets	 of	 £99k	 and	 share-based	 payment	 charges	 of	 £ 7 8k.	
As such, these results are in line with the external market forecast.
N e t	 f i n a n c e	 c o s t s	 h a v e	 i n c r e a s e d	 t o	 £ 3 0 6 k	 ( 2 0 0 8 :	 £ 1 7 5 k ) ,	 m a i n l y	
a s	 a	 r e s u l t	 o f	 a	 t r a n s l a t i o n	 l o s s	 o n	 U S	 d o l l a r	 b o r r o w i n g s ,	 g i v e n	 
t h e	 we a k e n i n g	 o f	 s t e r l i n g	 a g a i n s t	 t h e	 U S	 d o l l a r	 o v e r	 t h e	 c o u r s e	 
of the year. 
P r o f i t	 a f t e r	 t a x	 a m o u n t e d	 t o	 £ 22 1 k	 ( 2 0 0 8 :	 £ 2 3 8 k )	 w h i c h	 r e s u l t e d	
i n	 e a r n i n g s	 p e r	 s h a r e	 o f	 1 . 4p	 v e r s u s	 e a r n i n g s	 p e r	 s h a r e	 o f	 2 . 4p	
i n	 t h e	 p r e v i o u s	 y e a r .	
Balance sheet
T h e	 G r o u p	 h a s	 i n t a n g i b l e	 a s s e t s	 o f	 £ 4 . 9	 m i l l i o n	 ( 2 0 0 8 :	 £5 . 1	 m i l l i o n )	
at the year-end comprised of goodwill of £3.1 million and intangible 
a s s e t s	 o f	 £ 1 .8	 m i l l i o n ,	 s e p a r a t e l y	 i d e n t i f i e d	 i n	 l i n e	 w i t h	 c u r r e n t	 I F R S .	
T h e	 G r o u p	 h a s	 p e r f o r m e d	 a n	 i m p a i r m e n t	 r e v i e w	 u n d e r	 c u r r e n t	
a c c o u n t i n g	 s t a n d a r d s	 a n d	 i s	 c o m f o r t a b l e	 w i t h	 t h e	 c a r r y i n g	 v a l u e	 
o f	 i t s	 i n t a n g i b l e	 a s s e t s	 g i v e n	 t h e	 g r o w t h	 a n d	 r e s u l t s	 f o r	 t h e	 y e a r	 
just ended. 11 Overview Annual Report and Accounts 2009
www.omegadiagnostics.com
N e t	 d e b t	 ( t o t a l	 b o r r o w i n g s	 l e s s	 c a s h )	 r e d u c e d	 t o	 £ 1 . 6 4	 m i l l i o n	 f r o m	
£ 1 . 7 5	 m i l l i o n ,	 d e s p i t e	 t h e	 t r a n s l a t i o n	 l o s s	 o n	 c u r r e n c y	 b o r r o w i n g s	
r e f e r r e d	 t o	 a b o v e	 w h i c h	 a m o u n t e d	 t o	 £ 0 . 1 9	 m i l l i o n .
Research and development
T h e	 G r o u p	 s u c c e s s f u l l y	 d e v e l o p e d	 a n	 i m p r o v e d	 v e r s i o n	 o f	 t h e	
Genarrayt
™
 microarray system for food intolerance which allows 
laboratories to use significantly cheaper instrumentation to interpret 
r e s u l t s.	 T h i s	 h a s	 h e l p e d	 t h e	 r o l l - o u t	 o f	 t h i s	 a s s a y	 f o r	 e v a l u a t i o n	
p u r p o s e s	 w h i c h	 I	 h a v e	 r e f e r r e d	 t o	 e a r l i e r	 a n d	 w h e r e	 e n h a n c e d	
customer acceptance is expected as a result. The Group will 
continue to direct a large part of its effort in broadening the range 
of tests that can be performed on the microarray platform where 
t h e	 i m m e d i a t e	 p r i o r i t y	 e x i s t s	 t o	 d e v e l o p	 a	 p a n e l	 o f	 a u t o i m m u n e	 t e s t s.	
Elsewhere, the Group has expanded its range of control products 
which is seen as potentially beneficial in times of increasing 
monitoring of assay performance.
Board and management
As	 announced	 during	 the	 year ,	 Dr	 Mik e	 W alk er	 resigned	 on	 1 1	 November	
2008	 and	 the	 Board	 recorded	 its	 thanks	 to	 him	 at	 that	 time.	
A number of senior management appointments were made, either 
in the year, or just after to ensure the Group remains sufficiently 
r e s o u r c e d	 t o	 a c h i e v e	 i t s	 o b j e c t i v e s	 a n d	 I	 wo u l d	 l i k e	 t o	 t h a n k	 a l l	
e m p l o y e e s	 f o r	 t h e i r	 h a r d	 wo r k	 i n	 h e l p i n g	 t o	 a c h i e v e	 t h e	 r e s u l t s	
we	 h a v e	 r e p o r t e d .
Outlook
Trading in the first three months of the year is in line with current 
m a n a g e m e n t	 e x p e c t a t i o n .	 A s	 we	 m o v e	 f o r wa r d	 t h r o u g h o u t	 t h e	 
year we anticipate additional growth being generated through a 
c o m b i n a t i o n	 o f	 o r g a n i c	 a n d	 a c q u i s i t i v e	 g r o w t h .
Organic growth:
T h e	 p r i m a r y	 r o u t e	 a n d	 l e v e l	 o f	 o r g a n i c	 g r o w t h	 i s	 d e p e n d e n t	 u p o n	 
the rate of placement of new Genarrayt™ systems, which itself  
is dependent upon the upgrading of our manufacturing methods,  
a process which is ongoing.
Acquisitive growth:
O u r	 p r o p e n s i t y	 t o	 g r o w	 t h r o u g h	 a c q u i s i t i o n	 i s	 d e p e n d e n t	 u p o n	 t h e	
a v a i l a b i l i t y	 o f	 f i n a n c e	 a n d	 s u i t a b l e	 o p p o r t u n i t i e s.	 A	 n u m b e r	 o f	 h i g h	
q u a l i t y	 v a l u e	 e n h a n c i n g	 o p p o r t u n i t i e s	 a r e	 c u r r e n t l y	 b e i n g	 e v a l u a t e d .
I look forward to updating you throughout the year. 
David Evans, CA
Non - ex e c u ti ve	 Cha i r ma n
6	 J u l y	 2 0 0 9
T u r n o v e r 	 f o r 	 t h e	
Group increased  
t o 	 £ 5 . 4 	 m i l l i o n	
representing a 
headline growth of 
5 6 % 	 a n d 	 l i k e - f o r - l i k e	
g r o w t h 	 o f 	 2 0 % .
